L-histidinol reverses resistance to cisplatinum and other antineoplastics in a tumorigenic epithelial cell line

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3641-3646

  Warrington, Robert C ^a   Fang, Wei D ^a   Zhang, Lu ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Cisplatinum and antimetabolite; Kidney epithelial cells; L histidinol; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYTARABINE; FLUOROURACIL; HISTIDINOL;

ANIMAL CELL; ARTICLE; CELL STRAIN; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; EPITHELIUM CELL; KIDNEY EPITHELIUM; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CISPLATIN; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HISTIDINOL; IMIDAZOLES; PROTEIN SYNTHESIS INHIBITORS;

EID: 0030499038     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Warrington RC, Fang WD, Zhang L, Shieh M and Saier MH: L-Histidinol selectively modulates daunomycin toxicity in normal and tumorigenic kidney epithelial cells. Anitcancer Res 16: 3629-3634, 1996.
2. Warrington RC, Fang WD, Zhang L, Shieh M and Saier MH. Mimetics of L-histidinol which selectively modulate daunomycin toxicity in normal and tumorigenic epithelial cells. Anticancer Res 16: 3635-3640, 1996.
3. U HS, Boerner P, Rindler MJ, Chuman L and Saier MH: Characterization of chemically and virally transformed variants of Madin-Darby canine kidney (MDCK) epithelial cellsJ. Cell Phys. 122: 299-307, 1985.
4. Warrington RC: A novel approach for improving the efficacy of experimental cancer chemotherapy using combinations of anticancer drugs and L-histidinol. Anticancer Res 6: 451-464, 1986.
5. Warrington RC: L-Histidinol in experimental chemotherapy: improving the selectivity and efficacy of anticancer drugs, eliminating metastatic disease and reversing the multidrug-resistant phenotype. Biochem Cell Biol 70: 365-365, 1992.
6. Warrington RC: Modulation of anticancer drug toxicity by Lhistidinol: a route for improving human cancer chemotherapy? Drugs of the Future 18: 743-749, 1993.
7. Hill BT, Shellard SA, Hosking LK, Dempke WCW, FichtingerSchepman AMJ, Tone T, Scanlon KJ and Sheland RDH: Characterization of a cisplatin-resistant human ovarian carcinoma cell line expression cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexate. Cancer Res 52: 3110-3118, 1992.
8. Warrington RC, Cheng I and Fang WD: L-Histidinol increases the vulnerability of cultured human leukemia and lymphoma cells to anticancer drugs. Anticancer Res 13: 2107-2112, 1993.
9. Warrington RC, Cheng I and Fang WD: L-Histidinol increases the susceptibility of cultured human colon carcinoma cells to anticancer drugs. Anticancer Res 14: 2367-372 1994.
10. Warrington RC and Rang WD: Reversal of the multidrug-resistant phenotype of Chinese hamster ovary cells by L-histidinol. J Nat Cancer Inst 81: 798-803, 1989.
11. Cole SPC: The 1991 Merck Frosst Award. Multidrug resistance in small cell lung cancer. Can J Physiol Pharmacol 70: 313-329, 1991.
12. Lloyd D, Pool RK and Edwards SW: Implications of cell division cycle studies. 1. Cancer chemotherapy and the Cell Cycle. In: The Cell division cycle. Academic Press. New York, 1982. pp 419-428.
13. Chu G: Cellular responses to cisplatin. The roles of DNA binding proteins and repair. J Biol Chem 269: 787-790, 1994.
14. Comis RL: Cisplatin: the future. Sem Oncol 21 (suppl. 12): 109-113, 1994.
15. Warrington RC and Wratten N: Regulation of macromolecular synthesis in reovirus-infected L-929 cells: Effects of L-histidinol. J Virol 16: 1503-1511, 1975.
16. Warrington RC and Wratten N: Differential action of L-histidinol in reovirus-infected and uninfected L-929 cells. Virol 81: 408-418, 1974.
17. Warrington RC, Wratten N and Hechtman R: L-Histidinol inhibits specifically and reversibly ribosomal RNA and protein synthesis in mouse L cell. J Biol Chem 252: 5251-5257, 1977.
18. Huang M-T: Homoharringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 11: 511-519, 1975.
19. Warrell RP, Coonley CJ and Gee TS: An effective new drug for remission induction in refractory nonlymphocytic leukemia. J Clin Oncol 3: 617-621, 1985.
20. Warrington RC and Fang WD: Different effects of L-histidinol and homoharringtonine on 5-fluorouracil and bis-chloroethylnitrosourea activity in a murine model. Anticancer Res 11: 1879-1884, 1991.
21. Andrewa KS and Howell SB: Cellular pharmacology of cisplatinum: perpectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43, 1991.
22. Perez RP, Hamilton TC, Oxols RF and Young RC: Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer (Suppl) 71: 1572- 1580, 1993.
23. Endicott JA and Ling V: The biochemistry of P-glycoprotein mediated multidrug resistance. Ann Rev Biochem 58: 137-171, 1989.
24. Mitchell JB and Russo A: The role of glutathione in radiation and drug induced cytotoxicty. Br J Cancer 55 (Supp) 96: 104, 1987.